comprehensive -WSS

comprehensive

author：comprehensive 2025-09-01 15:19:42 - browse：91

the U.S. Medicare Handbook is photographed in Washington. — Pablo Martinez Monsivais/AP

Roughly 33.4 million adults older than 65 and people with disabilities were enrolled in a Medicare Advantage plan as the calendar flipped to 2024 — another year of steady, albeit slower, growth for the taxpayer-funded program.

Enrollment increased 7.1% year over year, which would make this year’s annual growth rate identical to last year’s, according to new federal Medicare Advantage enrollment data analyzed by STAT.

The data reinforce how America’s Medicare program continues to shift toward a more privatized version that has not saved any money for taxpayers, has been linked to inappropriate coding practices, and has restricted care for older and vulnerable patients. And even though the federal government made several changes to Medicare Advantage for 2024 — changes that were vehemently opposed by the health insurance industry — the program’s growth has not been stunted, nor did insurers dramatically slash their offerings.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Stories you might have missed in 2023: health, science, medicine

WSS

A $475,000 price tag for a new cancer drug: crazy or meh?

Apple Vision Pro: A first look at health apps on the new VR headset

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Stories you might have missed in 2023: health, science, medicine

In shift, Texas to cover initial consult for Afghan baby's gene therapy

focus

comprehensive

focus

Wildfire smoke exposes gaps in outdoor worker protections

Time to name cancers by genetics, not organ of origin, expert says

After affirmative action ruling, medical educators look to 'holistic review'

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

BioMarin wins approval for gene therapy to treat hemophilia A

Even great ERs can’t make up for American health disparities

Moonlake's readout produced a cash windfall. Risks remain

Boston Scientific acquires urology company Axonics for $3.7 billion

The cancer drug shortage isn’t new — and neither are the solutions

SAMSHA loosens regulations on methadone treatment centers

hotspot

Some dementia cases could be undiagnosed liver disease

ARCH Venture Partners is raising $3 billion for a life sciences fund

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Allen Institute goes after foundational questions, CEO Costa says

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

What we need to know about Arena Bioworks

focus

Wikipedia

hotspot

focus